

SCIENTIFIC PROGRAM

THURSDAY, JUNE 22

- 13.45 *Welcome*
- 14.00–15.35 SESSION I: ANTIDIABETIC DRUGS – DECISIONS FOR MODERN TREATMENT**
Chairs: I. Tkáč (Slovakia), J. Škrha (Czech Republic)
- 14.00–14.25 **Pharmacogenomic Aspects in the Treatment of Type 2 Diabetes**
I. Tkáč (Slovakia)
- 14.25–14.45 **Antidiabetic Agents and Cardioprotection**
O. Schnell (Germany)
- 14.45–15.10 **Renal Function and Gliflozin Treatment in Diabetes**
C. Wanner (Germany)
- 15.10–15.30 **Why We Still Need to Study Metformin?**
I. Konrade (Latvia)
- 15.30–16.00 **Coffee break and poster session I (posters P01-P05, see page 13)**
Moderator: E. Hatzigelaki (Greece)
- 16.00–17.30 SESSION II: THE WAY TO PROPER DIAGNOSIS**
Chairs: N. Schloot (Germany), K. Kaňková (Czech Republic)
- 16.00–16.25 **How to Classify Diabetes?**
N. Schloot (Germany)
- 16.25–16.45 **Diagnosis of Maturity Onset Diabetes of the Young (MODY) in the Czech Republic**
Š. Průhová (Czech Republic)
- 16.45–17.10 **Viruses, Bacteria and Type 1 Diabetes**
O. Cinek (Czech Republic)
- 17.10–17.30 **Non-Diabetic Hypoglycemia as a Source of Diagnostic Confusions**
J. Škrha (Czech Republic)
- 18.00–19.00 SESSION SPONSORED BY BOEHRINGER INGELHEIM**
RELEVANCE OF CV OUTCOMES WITH EMPAGLIFLOZIN IN CLINICAL PRACTICE – ADDING VALUE TO CURRENT STANDARD OF CARE IN TYPE 2 DIABETES
- 18.00–18.20 **Glucose Lowering and CV Mortality Reduction – Fulfilling the Desired Need for Better Outcomes in Diabetes Treatment**
M. Prázný (Czech Republic)
- 18.20–18.40 **Guidelines and Clinical Practice – Enhancing CV Protection in Patients with Type 2 Diabetes**
H. Drexel (Austria)
- 18.40–19.00 **Open Forum**

9.00–10.30	SESSION III: THE MAIN PLAYERS IN METABOLIC REGULATIONS <i>Chairs: M. Roden, M. Hanefeld (Germany)</i>
9.00–9.25	Organ Cross Talk – Muscle, Liver and Adipose Tissue <i>M. Roden (Germany)</i>
9.25–9.50	Targeting the Gastrointestinal Tract to Treat Diabetes <i>M. Haluzík (Czech Republic)</i>
9.50–10.10	The Impact of Liver Disease on Diabetes Treatment <i>E. Hatziagelaki (Greece)</i>
10.10–10.30	Frailty as Guide for Individualized Treatment in Old Patients with Type 2 Diabetes <i>M. Hanefeld (Germany)</i>
10.30–11.00	Coffee break and poster session II (posters P06-P11, see pages 13-14) <i>Moderator: T. Stulnig (Austria)</i>
11.00–12.30	SESSION IV: PAVEMENT TO VASCULAR DISEASE <i>Chairs: P. Nawroth, H. Schatz (Germany)</i>
11.00–11.30	Diabetic Complications – No Way of Return? <i>P. Nawroth (Germany)</i>
11.30–11.50	Do We Have Reliable Biomarkers Disclosing Diabetic Complications? <i>J. Škrha jr. (Czech Republic)</i>
11.50–12.10	Indicators of Diabetic Kidney Disease <i>K. Kaňková (Czech Republic)</i>
12.10–12.30	Dyslipidemia, Diabetes and Atherosclerosis <i>H. Schatz (Germany)</i>
12.30–14.00	Lunch
12.30–13.30	SESSION SPONSORED BY MEDTRONIC
12.30–13.15	Exercise on 640G – New Thinking, New Challenges, More Possibilities? <i>T. Klupa (Poland)</i>
13.15–13.30	Discussion
13.30–14.00	Poster session III (posters P12-P18, see page 14) <i>Moderator: I. Konrade (Latvia)</i>

14.00–15.30	SESSION V: NEURAL TISSUE AND WOUNDS – TARGETS FOR TREATMENT <i>Chairs: P. Kempler (Hungary), D. Ziegler (Germany)</i>
14.00–14.25	Diabetic Neuropathy – The Relation to Vascular Disease <i>P. Kempler (Hungary)</i>
14.25–14.50	Modern Treatment of Diabetic Neuropathy <i>D. Ziegler (Germany)</i>
14.50–15.10	Local Application of Stem Cells in Wound Healing <i>R. Bém (Czech Republic)</i>
15.10–15.30	Clinical Outcome of Stem Cell Therapy in Critical Limb Ischemia in Diabetic Patients <i>M. Dubský (Czech Republic)</i>
15.30–16.00	Coffee break and poster session IV (posters P19-P23, see pages 14-15) <i>Moderators: T. Stulnig (Austria), I. Konrade (Latvia)</i>
16.00–17.30	SESSION VI: TECHNOLOGIES – PROMISING DREAMS AND REALITY <i>Chairs: R. Hovorka (UK), M. Prázný (Czech Republic)</i>
16.00–16.30	Advances in Closed-Loop System in Diabetes <i>R. Hovorka (UK)</i>
16.30–16.50	Role of Glucose Variability as the Target for Treatment <i>M. Prázný (Czech Republic)</i>
16.50–17.10	Optimising Diabetes Control in Children: Technologies and Beyond <i>Z. Šumník (Czech Republic)</i>
17.10–17.30	Practical Implementation of CGM and Insulin Pump Therapy <i>J. Šoupal (Czech Republic)</i>
17.35–18.35	SESSION SPONSORED BY ELI LILLY PATIENT FOCUSED INNOVATION IN THE TREATMENT OF DIABETES MELLITUS
17.35–17.40	Welcome <i>I. Benešová (Czech Republic)</i>
17.40–18.05	Innovation in Insulin Therapy <i>K. Štechová (Czech Republic)</i>
18.05–18.30	GLP-1-RA Therapy Tailored to Individual Patient Needs <i>M. Haluzík (Czech Republic)</i>
18.30–18.35	Discussion

9.00–10.30	SESSION VII: HOW TO SUBSTITUTE DISTURBED FUNCTION IN DIABETES <i>Chairs: R. Lehmann (Switzerland), I. Rychlík (Czech Republic)</i>
9.00–9.25	Beta-Cell Replacement Therapy <i>R. Lehmann (Switzerland)</i>
9.25–9.50	Transplantation Program in Diabetes in the Czech Republic <i>P. Girman (Czech Republic)</i>
9.50–10.15	Dialysis Treatment in the Czech Republic <i>I. Rychlík (Czech Republic)</i>
10.15–10.30	Obstructive Sleep Apnea in Diabetes – Causation or Association? <i>J. Polák (Czech Republic)</i>
10.30–11.00	Coffee break
11.00–12.30	SESSION VIII: PERSPECTIVES FOR DIABETIC PATIENTS <i>Chairs: E. Standl (Germany), W. Waldhäusl (Austria)</i>
11.00–11.25	What Is the Evidence for Primary and Secondary Prevention of Cardiovascular Events in Patients with T2DM? The Cardiologist Perspective <i>A. Gitt (Germany)</i>
11.25–11.50	The Rollercoaster History of Turning Incretin Hormones into Helpful Medications for the Treatment of Type 2 Diabetes <i>M. Nauck (Germany)</i>
11.50–12.15	Management of Type 2 Diabetic Patients with Cardiovascular Disease – An Updated View <i>E. Standl (Germany)</i>
12.15–12.30	The Theoretical Basis for Prevention of Beta-Cell Damage in Type 2 Diabetic Patients <i>M. Anděl (Czech Republic)</i>
12.30–12.45	Closing and invitation to the next meeting

POSTER SESSIONS

Poster session I (Thursday, June 22, 15.30–16.00)

Moderator: E. Hatzigelaki (Greece)

P01. Abnormalities of Thiamine Metabolism Induced by Diabetes and Kidney Dysfunction in Micro- and Macrovascular Cells

K. Chalásová, L. Pácal, K. Kaňková (Czech Republic)

P02. Association Between Acylcarnitine Concentration and Muscle Insulin Resistance

I. Konrade, E. Makarova, G. Dambrova, I. Kalere, K. Vilks, K. Vojska, M. Dambrova (Latvia)

P03. Increased Oxidative Stress and Endothelial Activation in Diabetic Neuropathy in Patients with Type 1 Diabetes Mellitus

J. Škrha jr., T. Pelcl, J. Šoupal, M. Kalousová, M. Prázný, J. Škrha (Czech Republic)

P04. MicroRNA-196 and -423 Have Different Expressions in Pancreatic Cancer Patients Compared to Those with Chronic Pancreatitis

P. Škrha, A. Hořínek, P. Frič, J. Hajer, M. Anděl, J. Škrha (Czech Republic)

P05. Severe Diabetic Ketoacidosis and Phosphate Deficiency

P. Tesinsky, A. Haken (Czech Republic)

Poster session II (Friday, June 23, 10.30–11.00)

Moderator: T. Stulnig (Austria)

P06. The Level of Metabolic Control (HBA1C) in Patients with Type 1 Diabetes Mellitus in the Czech Republic and Slovak Republic: Results of an International, Multicenter, Observational Study (DIAINFORM)

J. Broz, D. Janickova Zdarska, J. Urbanova, M. Brabec, B. Krivska, V. Donicova, R. Stepanova, E. Martinka, M. Kvapil (Czech Republic, Slovakia)

P07. The Level of Metabolic Control (HBA1C) in Insulin-Treated Patients with Type 2 Diabetes Mellitus in the Czech Republic and Slovak Republic: Results of a Multinational, Multicenter, Observational Study (DIAINFORM)

J. Broz, D. Janickova Zdarska, J. Urbanova, M. Brabec, B. Krivska, V. Donicova, R. Stepanova, E. Martinka, M. Kvapil (Czech Republic, Slovakia)

P08. FINDRISK as a Screening Tool for Diabetes in the Community: First Application in Cyprus

C. Chrysostomou, A. Ioannou, G. Lavranos (Cyprus)

P09. Differences in Approach to Screening for Gestational Diabetes – National Patient Survey on Screening for Gestational Diabetes in the Czech Republic

P. Šimjak, K. Anderlová, H. Krejčí, A. Pařízek, P. Pařízková, V. Krejčí, M. Kršek, M. Mráz, M. Haluzík (Czech Republic)

P10. Hypoglycaemia Frequency and Glycaemic Outcomes in Type 2 Diabetes (T2DM) Using Different Fasting Plasma Glucose Titration Targets: An Analysis of Studies with Insulin Glargine 100 U/ml

D.R. Owens, B.M. Frier, J. Chao, R. Perfetti, W. Landgraf (UK, USA, Germany)

P11. Software Module for Automatic Detection of Decrease in Glycaemia Associated with Higher Intensity of Physical Activity in Data from Activity Trackers and CGM Used by Patients with Type 1 Diabetes

A. Holubová, J. Mužík, M. Poláček, J. Kašpar, K. Hána, P. Smrčka, J. Brož (Czech Republic)

Poster session III (Friday, June 23, 13.30–14.00)

Moderator: I. Konrade (Latvia)

P12. TRPV4 Modulates Insulin mRNA Expression and Cell Death in Insulin Producing INS-1E Cells

M. Billert, M. Skrzypski, T. Wojciechowicz, M. Strowski, K.W. Nowak (Poland, Germany)

P13. Associations Between Biomarkers of Subclinical Inflammation and Depressive Symptoms in Patients with Type 1 And Type 2 Diabetes

C. Herder, A. Schmitt, F. Budden, A. Reimer, B. Kulzer, M. Roden, T. Haak, N. Hermanns (Germany)

P14. Tumor Necrosis Factor Induces Syndecan 4 Expression in Adipocytes from Subcutaneous Adipose Tissue During Surgically-Induced Weight Loss

A. Jürets, B.K. Itariu, M. Keindl, L. Leitner, G. Prager, F. Lange, V. Grablowitz, M. Zeyda, T.M. Stulnig (Austria)

P15. Decreased CCL2 (MCP-1) Secretion of Leucocytes in LADA Compared to Type 1 and Type 2 Diabetes

M. Ooms, A. Strom, K. Strassburger, B. Menart, N.C. Schloot (Germany)

P16. Bone Turnover Markers in Serum Correlate with Indices of Glycemic Regulation in Obesity

B.K. Itariu, R. Marculescu, P. Pietschman, G. Prager, T.M. Stulnig (Austria)

P17. Osteopontin Is Overexpressed in NAFLD-Induced Hepatocellular Carcinoma and Might Modulate Liver Inflammation and Macrophage Activation

A.D. Nardo, N.G. Grün, M. Zeyda, T.M. Stulnig (Austria)

P18. Diabetes Mellitus and Hypothyreosis as Potential Drivers of Colorectal Cancer Progression and Mortality: View of the Pathologist

M. Powell, P. Srna, P. Dunder, Z. Špůrková, P. Heneberg (Czech Republic)

Poster session IV (Friday, June 23, 15.30–16.00)

Moderators: T. Stulnig (Austria), I. Konrade (Latvia)

P19. Association of Charcot Osteoarthropathy Complications with Treatment Modalities and Early Diagnosis

M. Flekac, P. Trachta, M. Prazny (Czech Republic)

P20. The Daily Basal Insulin Requirement in Insulin Pump Therapy and Association with Metabolic Control, Age and BMI in Adult Type 1 Diabetes Mellitus Treated with Personal Insulin Pumps

B. Matejko, A. Kukułka, T. Klupa (Poland)

P21. Impact of Incretins in People with Type 2 Diabetes on Insulin Pumps

R. Chlup, J. Zapletalova, T.S. Cheng, Z. Ramik, M. Slezakova, H. Zalesakova (Czech Republic)

P22. Hyperglycaemic Coma as a Primomanifestation of Diabetes Mellitus - Case Report

J. Křížová, P. Trachta, E. Kotrlíková (Czech Republic)

P23. Structured Group Programme Improves Metabolic Control and Psychological Status in People with Diabetes

J. Stefankova, A. Jirkovska, T. Hrachovinova, A. Adamikova, J. Hradec, J. Jirkovska, K. Cechova, V. Havlova, R. Rihankova (Czech Republic)